‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient’s response to immunotherapy. Now, Johns Hopkins investigators have found that a subset of mutations within the overall TMB, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors more likely to respond to immunotherapy. Read more here.

SEE ALL NEWS
Recent Posts
Podcast: Colorectal Cancer Why age matters when it comes to cancer Liquid Biopsy Predicts Response in Patients with Advanced Lung Cancer Experimental Drug Combination Shows Promise Against Hard-to-Treat Tumors What are the risk factors for Pancreatic Cancer? New Lung Tumor Scoring System Prostate Cancer: Advancements in Screenings 5 Healthy Habits That Help You During Lung Cancer Treatment Six Mammogram Myths